epcoritamab
abbvie,genmab
['lymsm', 'dlbcl', 'epcoritamab']
epcoritamab plus r-dhax/c demonstrates high response rates and manageable safety in dlbcl #eha22 #lymsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.